CUBT (Curative Biotechnology) ROE % Adjusted to Book Value: 0.00% (As of Mar. 2023)


What is Curative Biotechnology ROE % Adjusted to Book Value?

Curative Biotechnology CUBT +19.71% ROE % Adjusted to Book Value is 0.00% as of Mar. 2023.

Curative Biotechnology's ROE % for the quarter that ended in Mar. 2023 was 0.00%. Curative Biotechnology's PB Ratio for the quarter that ended in Mar. 2023 was N/A. Curative Biotechnology's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2023 was N/A.

Curative Biotechnology ROE % Adjusted to Book Value Related Terms

Curative Biotechnology ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Curative Biotechnology's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curative Biotechnology ROE % Adjusted to Book Value Chart

Curative Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE % Adjusted to Book Value
Get a 7-Day Free Trial 0.00 Negative Equity 0.00 0.00 0.00

Curative Biotechnology Quarterly Data
Dec16 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CUBT vs ORGS, SNSE, TNXP: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Curative Biotechnology's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curative Biotechnology ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curative Biotechnology's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Curative Biotechnology's ROE % Adjusted to Book Value falls into.


Curative Biotechnology ROE % Adjusted to Book Value Calculation

Curative Biotechnology's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Curative Biotechnology's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Curative Biotechnology (CUBT) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2023. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Curative Biotechnology and its competitors.
Is Curative Biotechnology's ROE % Adjusted to Book Value too high?
Curative Biotechnology's current ROE % Adjusted to Book Value is 0.00%.
How does Curative Biotechnology's ROE % Adjusted to Book Value compare to ORGS and SNSE?
Curative Biotechnology's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Curative Biotechnology and its competitors. Curative Biotechnology's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curative Biotechnology stock overvalued right now?
Curative Biotechnology (CUBT) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Curative Biotechnology (CUBT), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curative Biotechnology Business Description

Address 3801 PGA Boulevard, Suite 600, Palm Beach Gardens, FL, USA, 33410
Curative Biotechnology Inc is a development-stage biomedical company focusing on novel treatments for rare diseases. The Company is identifying, acquiring, and developing disease-modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech currently has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro-oncology. The Company is now concentrating its energy and resources on its degenerative eye disease platform.